Kakodkar Rahul, Soin A S
Institute of Liver Transplantation and Regenerative Medicine, Medanta-the Medicity, Sector 38, Gurgaon, Haryana 122001 India.
Indian J Surg. 2012 Feb;74(1):100-17. doi: 10.1007/s12262-011-0387-2. Epub 2011 Dec 27.
Hepatocellular carcinoma (HCC) often occurs in patients with chronic liver disease or cirrhosis. Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver. Limitations in organ availability, necessitate stringent selection of patients who would likely to derive most benefit. Selection criteria have considered tumor size, number, volume as well as biological features. The Milan criteria set the benchmark for tumors that would benefit from liver transplantation but were found to be excessively restrictive. Modest expansion in criteria has also been shown to be associated with equivalent survival. Microvascular invasion is the single most important adverse prognostic factor for survival. Living donor liver transplantation has expanded donor options and has the advantage of lower waiting period and not impacting the non-HCC waiting list. Acceptable outcomes have been obtained with living donor liver transplantation for larger and more numerous tumors in the absence of microvascular invasion. Downstaging of tumors to prevent progression while waiting for an organ or for reduction in size to allow enrolment for transplantation has met with variable success.
肝细胞癌(HCC)常发生于慢性肝病或肝硬化患者。肝细胞癌的肝移植有可能消除肿瘤以及潜在的肝硬化,是肝硬化肝脏中HCC以及非肝硬化肝脏中巨大HCC的理想治疗方法。器官供应的限制使得必须严格挑选可能获益最大的患者。选择标准考虑了肿瘤大小、数量、体积以及生物学特征。米兰标准为可从肝移植中获益的肿瘤设定了基准,但被发现限制过严。标准的适度放宽也显示与同等生存率相关。微血管侵犯是生存的唯一最重要的不良预后因素。活体肝移植扩大了供体选择范围,具有等待期较短且不影响非HCC等待名单的优势。对于无微血管侵犯的更大、更多肿瘤,活体肝移植已取得了可接受的结果。在等待器官期间对肿瘤进行降期以防止进展或缩小尺寸以允许纳入移植,取得了不同程度的成功。